Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2022.0310

Commentary

Latest advances in evidence-based cancer management.

Prof. Dr. Ε. Hanisch, MD, PhD.

 

Abstract
Multimodal treatment of patients with early and advanced -stage solid tumors has been standardized leading to oncological outcome improvement. Recently, many multigene assays have been approved by the FDA for tumor genomic profiling while a few only gene panels for circulating tumor DNA (ctDNA) testing have been integrated in the treatment of advanced solid tumors. These multigene assays are widely used as predictive biomarkers to select patients for individualized treatment. Here are discussed latest advances in patient selection to guide targeted therapy or immunotherapy with pembrolizumab, nivolumab, and atezolizumab.

(Citation: Gastric & Breast Cancer 2020; 17(1): 6-11)
Back  

 

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 10 February 2022